Trade Niagen Bioscience Inc - NAGE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0266 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.9217 |
| Open | 7.8217 |
| 1-Year Change | 229.2% |
| Day's Range | 7.7517 - 7.8817 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 18, 2025 | 7.8517 | 0.0200 | 0.26% | 7.8317 | 7.9017 | 7.7317 |
| Mar 17, 2025 | 7.9217 | 0.0900 | 1.15% | 7.8317 | 7.9817 | 7.6617 |
| Mar 14, 2025 | 7.8317 | 0.0900 | 1.16% | 7.7417 | 7.8817 | 7.5617 |
| Mar 13, 2025 | 7.7017 | 0.0300 | 0.39% | 7.6717 | 7.7517 | 7.3117 |
| Mar 12, 2025 | 7.8117 | 0.0100 | 0.13% | 7.8017 | 7.9717 | 7.7917 |
| Mar 11, 2025 | 7.8817 | 0.0000 | 0.00% | 7.8817 | 8.1717 | 7.6117 |
| Mar 10, 2025 | 7.8717 | 0.2000 | 2.61% | 7.6717 | 8.0217 | 7.5617 |
| Mar 7, 2025 | 7.6817 | -0.0800 | -1.03% | 7.7617 | 7.9817 | 7.3417 |
| Mar 6, 2025 | 7.6817 | -0.4600 | -5.65% | 8.1417 | 8.4817 | 7.5417 |
| Mar 5, 2025 | 8.5417 | 1.8900 | 28.41% | 6.6517 | 9.1517 | 6.6517 |
| Mar 4, 2025 | 5.5917 | 0.1000 | 1.82% | 5.4917 | 5.6917 | 5.2417 |
| Mar 3, 2025 | 5.5017 | -0.1200 | -2.13% | 5.6217 | 5.9117 | 5.4417 |
| Feb 28, 2025 | 5.6217 | 0.2100 | 3.88% | 5.4117 | 5.6717 | 5.4117 |
| Feb 27, 2025 | 5.4317 | -0.1700 | -3.03% | 5.6017 | 5.6917 | 5.4217 |
| Feb 26, 2025 | 5.6417 | 0.2100 | 3.87% | 5.4317 | 5.7717 | 5.4117 |
| Feb 25, 2025 | 5.4317 | 0.0300 | 0.56% | 5.4017 | 5.5017 | 5.3217 |
| Feb 24, 2025 | 5.4917 | 0.0800 | 1.48% | 5.4117 | 5.5217 | 5.2417 |
| Feb 21, 2025 | 5.4017 | -0.3200 | -5.59% | 5.7217 | 5.7517 | 5.4017 |
| Feb 20, 2025 | 5.6817 | -0.1100 | -1.90% | 5.7917 | 5.8017 | 5.5417 |
| Feb 19, 2025 | 5.8317 | 0.0500 | 0.86% | 5.7817 | 5.8717 | 5.6617 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Chromadex Corp Company profile
About Chromadex Corp
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Chromadex Corp revenues increased 14% to $67.4M. Net loss increased 36% to $27.1M. Revenues reflect Consumer Products Segments increase of 20% to $56.7M, Analytical Reference Standards and Service segment increase of 12% to $3.3M. Higher net loss reflects Corporate and other segment loss increase of 19% to $36.4M, Ingredients Segments income decrease of 27% to $3.7M.
Equity composition
Common Stock $.001 Par, 08/11, 150M auth., 60,875,325 issd. Insiders & Strategic holders own 45.88%. 04/16, 1-for-3 recerse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
10900 Wilshire Blvd
Suite 600
LOS ANGELES
CALIFORNIA 90024
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com